Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MTTP | P55157 | 11/20 | 0.45 |
| ▸ | APOB | P04114 | 4/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12082658 | 0.92 | KDM4E (0.51) | KDM4EGAASMN1; SMN2MTTPAPOB | |
| SCHEMBL14511189 | 0.89 | KDM4E (0.48) | KDM4EGAASMN1; SMN2MTTPAPOB | |
| SCHEMBL14511177 | 0.87 | KDM4E (0.46) | KDM4EGAASMN1; SMN2MTTPAPOB | |
| SCHEMBL12082736 | 0.86 | GAA (0.53) | KDM4EGAASMN1; SMN2MTTPAPOB | |
| SCHEMBL14511190 | 0.85 | MTTP (0.47) | KDM4EGAASMN1; SMN2MTTPAPOB | |
| SCHEMBL14511168 | 0.85 | MTTP (0.48) | KDM4EGAASMN1; SMN2MTTPAPOB | |
| SCHEMBL14511148 | 0.85 | MTTP (0.48) | KDM4EGAASMN1; SMN2MTTPAPOB | |
| SCHEMBL14511167 | 0.85 | MTTP (0.48) | KDM4EGAASMN1; SMN2MTTPAPOB | |
| SCHEMBL14511187 | 0.84 | MTTP (0.47) | KDM4EGAASMN1; SMN2MTTPAPOB | |
| SCHEMBL12082677 | 0.84 | KDM4E (0.50) | KDM4EGAASMN1; SMN2MTTPAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772494-B2 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-07-08 | — | — | US | disclosed |
| US-8772494-B2 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-07-08 | — | — | US | disclosed |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | APOB, PNLIP, LIPC | KDM4E 1451/4885GAA 323/4885SMN1; SMN2 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.